|
rs28934578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Using the SKBR3 breast cancer and p53-null H1299 lung cancer cells stably expressing the R175H p53 mutant protein, we demonstrated that GON triggers the appearance of a wild-type-like p53 protein by using conformation-specific antibodies, immunoprecipitation, DNA-binding assays and target gene expression. p53 restoration was associated with a G2/M arrest, senescence, reduced cell migration, invasion and increased cell death.
|
30010803 |
2018 |
|
rs28934578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Using the MMTV-ERBB2;mutant p53 (R175H) in vivo mouse model of ERBB2-positive breast cancer, together with mouse and human cell lines, we compared lapatinib-resistant vs. lapatinib-sensitive tumor cells biochemically and by kinome arrays and evaluated their viability in response to a variety of compounds affecting heat shock response.
|
29799521 |
2018 |
|
rs28934578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
None of the intronic mutations has shown significant association with the breast cancer, two exonic mutations G13203A (rs28934578) and A14572G are significantly (P = 0.04, P = 0.007) associated with breast cancer.
|
24929325 |
2014 |
|
rs28934578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
These findings provide the basis for R175H to promote the initiation of breast cancer by expanding MESCs.
|
22824795 |
2013 |
|
rs28934578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
We found that zinc re-established chemosensitivity in breast cancer SKBR3 (expressing R175H mutation) and glioblastoma U373MG (expressing R273H mutation) cell lines.
|
21508668 |
2011 |
|
rs28934576
|
|
|
0.740 |
GeneticVariation |
BEFREE |
These results indicate that mtp53 R273H and PARP1 interact with replicating DNA and should be considered as dual biomarkers for identifying breast cancers that may respond to combination PARPi treatments.
|
31776133 |
2020 |
|
rs28934576
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Mutation R273H confers p53 a stimulating effect on the IGF-1R-AKT pathway via miR-30a suppression in breast cancer.
|
26898459 |
2016 |
|
rs28934576
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Expression of mutant p53 (mtp53) R273H associates with increased cell elasticity, survival under serum deprivation conditions, and increased Poly (ADP ribose) polymerase 1 (PARP1) on the chromatin in the AA-derived TNBC breast cancer cell line MDA-MB-468.
|
26703669 |
2015 |
|
rs28934576
|
|
|
0.740 |
GeneticVariation |
BEFREE |
We found that zinc re-established chemosensitivity in breast cancer SKBR3 (expressing R175H mutation) and glioblastoma U373MG (expressing R273H mutation) cell lines.
|
21508668 |
2011 |
|
rs11540652
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
|
26703669 |
2015 |
|
rs11540652
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The R248Q mutant co-localized with amyloid-like species in a breast cancer sample, which further supported its prion-like effect.
|
22715097 |
2012 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings cannot support contribution of rs1042522 polymorphism to breast cancer risk in an Iranian population.
|
31721533 |
2020 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The findings of our case-control study and meta-analysis suggest a significant association between p53 Arg72Pro polymorphism and an increased risk of breast cancer in Indian population.
|
30065615 |
2018 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 5 tagging single-nucleotide polymorphisms (rs2299941 of PTEN, rs2735385, rs6999227, rs1805812, and rs1061302 of Nijmegen breakage syndrome 1) were tightly associated with breast cancer risk in sporadic cases, and 5 other tagging single-nucleotide polymorphisms (rs1042522 of TP53, rs2735343 of PTEN, rs7220719, rs16945628, and rs11871753 of BRCA1-interacting protein 1) were tightly associated with breast cancer risk in familial and early-onset cases.
|
30799775 |
2018 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The findings of our case-control study and meta-analysis suggest a significant association between p53 Arg72Pro polymorphism and an increased risk of breast cancer in Indian population.
|
30065615 |
2018 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The findings of our case-control study and meta-analysis suggest a significant association between p53 Arg72Pro polymorphism and an increased risk of breast cancer in Indian population.
|
30065615 |
2018 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our finding suggests that TP53 (Arg72Pro) polymorphism may play a significant role as risk factor for breast cancer in north Indian breast cancer patients.
|
26553387 |
2016 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequency of the rs1042522 polymorphism of TP53 was significantly higher in all groups of patients with breast cancer compared with the control group.
|
27644661 |
2016 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A significant association was found between TP53Arg72Pro (rs1042522) and CDH1 -160 C/A (rs16260) polymorphisms and breast cancer risk.
|
26666818 |
2016 |